Oncohematology (OH) patients are supported by the intensive care unit (ICU). Admission of OH patients to the ICU is frequently delayed. Now, improvements in diagnosis and treatment, specific mutations, stem cell transplants, and immunotherapy have changed the outlook. A descriptive, retrospective cohort analysis was conducted on the population of adult patients with OH who were admitted to the ICU from January 2009 to February 2021. Assessing mortality in the ICU was the key result. The secondary result was connected to demographic and clinical factors such as age, sex, underlying (OH) illness, transplant, shock, sepsis, mechanical ventilation (MV), hemodialysis, sensory impairment, neutropenia, bacteremia, and APACHE II score with ICU mortality.
A total of 206 OH patients participated in the trial. There were 113 patients, mostly men (54%), with a median age of 59 years (IQR: 46-68). The specific number of days in the hospital was 15, whereas the median number of days in the intensive care unit was 5. (3-8). At the time of ICU release, mortality was estimated to be 45% (93 patients), 47% after 30 days, and 49% after 60 days. The average lifespan of people worldwide was 15.5 days (IQR: 4.25-60). The average APACHE II score was 22. (IQR: 15-25). In the multivariate analysis for mortality, there was a statistically significant correlation between the need for MV (P=0.021) and the APACHE II variables (P=0.0001). The APACHE II score value of 22 was determined to have the highest statistical significance using the ROC curve approach. The log-rank test technique was applied to compare patients with values larger or lower than 22. In terms of days, the median survival was (IQR): NR 5.5 versus HR 8.423, 95% CI 5.414 – 13.1, (P<0.0001).
The value of 22 points on the APACHE II and the need for MV helped differentiate the survival expectations between the two patient groups. In addition, the report detailed the 12 years of OH patients treated at UCI from underdeveloped nations.